TY - JOUR
T1 - Proceedings of the second international molecular pathological epidemiology (MPE) meeting
AU - Ogino, Shuji
AU - Campbell, Peter T.
AU - Nishihara, Reiko
AU - Phipps, Amanda I.
AU - Beck, Andrew H.
AU - Sherman, Mark E.
AU - Chan, Andrew T.
AU - Troester, Melissa A.
AU - Bass, Adam J.
AU - Fitzgerald, Kathryn C.
AU - Irizarry, Rafael A.
AU - Kelsey, Karl T.
AU - Nan, Hongmei
AU - Peters, Ulrike
AU - Poole, Elizabeth M.
AU - Qian, Zhi Rong
AU - Tamimi, Rulla M.
AU - Tchetgen Tchetgen, Eric J.
AU - Tworoger, Shelley S.
AU - Zhang, Xuehong
AU - Giovannucci, Edward L.
AU - van den Brandt, Piet A.
AU - Rosner, Bernard A.
AU - Wang, Molin
AU - Chatterjee, Nilanjan
AU - Begg, Colin B.
N1 - Funding Information:
We thank all of the members of the program committee, the speakers, the discussants, and the other participants of the Second International MPE Meeting on December 4–5, 2014 in Boston, MA, USA. We thank the Dana–Farber Cancer Institute (Edward J. Benz, Jr., President and CEO) for providing the meeting venue and the Department of Pathology, the Brigham and Women’s Hospital (Jeffrey A. Golden, Chairperson), and Enzymatics, Inc., for providing meals and refreshments, respectively. We also thank the Department of Pathology, the Brigham and Women’s Hospital (Jeffrey A. Golden, Chairperson); the Department of Epidemiology, the Harvard T.H. Chan School of Public Health (Michelle A. Williams, Chairperson); the Dana–Farber Harvard Cancer Center (Giovanni Parmigiani, Meir J. Stampfer, Lorelei A. Mucci, Deborah Schrag, and Charles S. Fuchs; Program Leaders); and the Channing Division of Network Medicine, the Department of Medicine, the Brigham and Women’s Hospital (Edwin K. Silverman, Division Chief) for providing morale supports and helping in announcements. This work was supported in part by grants from the US National Institute of Health (NIH) [R01 CA151993 (to SO), K07 CA190673 (to RN), R01 CA137178 (to ATC), K24 DK098311 (to ATC), and K07 CA172298 (to AIP)], and the friends of the Dana–Farber Cancer Institute (to SO). ATC is Damon Runyon Clinical Investigator. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funders (including Enzymatics, Inc.) did not have any role in planning the meeting, the decision to submit the manuscript for publication, or the writing of the manuscript. Use of Human Genome Organisation (HUGO) Gene Nomenclature Committee (HGNC)-approved symbols for genes and gene products: We use symbols approved by HGNC and described at www.genenames.org ; those include BRAF, CD274, ERBB2, ESR1, FASN, KRAS, MLH1, PDCD1LG2, PGR, PIK3CA, and VHL. Gene names are italicized, while names of gene products are non-italicized. Non-official names are described in parenthesis where helpful.
Funding Information:
The Second International MPE Meeting was sponsored in part by Enzymatics, Inc. ATC previously served as a consultant for Bayer Healthcare, Millennium Pharmaceuticals, Pozen Inc, and Pfizer Inc. The work was not funded by Enzymatics, Inc, Bayer Healthcare, Millennium Pharmaceuticals, Pozen Inc, or Pfizer Inc. All of the other authors declare no conflict of interest.
Publisher Copyright:
© 2015, Springer International Publishing Switzerland.
PY - 2015/7/13
Y1 - 2015/7/13
N2 - Disease classification system increasingly incorporates information on pathogenic mechanisms to predict clinical outcomes and response to therapy and intervention. Technological advancements to interrogate omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, metagenomics, interactomics, etc.) provide widely open opportunities in population-based research. Molecular pathological epidemiology (MPE) represents integrative science of molecular pathology and epidemiology. This unified paradigm requires multidisciplinary collaboration between pathology, epidemiology, biostatistics, bioinformatics, and computational biology. Integration of these fields enables better understanding of etiologic heterogeneity, disease continuum, causal inference, and the impact of environment, diet, lifestyle, host factors (including genetics and immunity), and their interactions on disease evolution. Hence, the Second International MPE Meeting was held in Boston in December 2014, with aims to: (1) develop conceptual and practical frameworks; (2) cultivate and expand opportunities; (3) address challenges; and (4) initiate the effort of specifying guidelines for MPE. The meeting mainly consisted of presentations of method developments and recent data in various malignant neoplasms and tumors (breast, prostate, ovarian and colorectal cancers, renal cell carcinoma, lymphoma, and leukemia), followed by open discussion sessions on challenges and future plans. In particular, we recognized need for efforts to further develop statistical methodologies. This meeting provided an unprecedented opportunity for interdisciplinary collaboration, consistent with the purposes of the Big Data to Knowledge, Genetic Associations and Mechanisms in Oncology, and Precision Medicine Initiative of the US National Institute of Health. The MPE meeting series can help advance transdisciplinary population science and optimize training and education systems for twenty-first century medicine and public health.
AB - Disease classification system increasingly incorporates information on pathogenic mechanisms to predict clinical outcomes and response to therapy and intervention. Technological advancements to interrogate omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, metagenomics, interactomics, etc.) provide widely open opportunities in population-based research. Molecular pathological epidemiology (MPE) represents integrative science of molecular pathology and epidemiology. This unified paradigm requires multidisciplinary collaboration between pathology, epidemiology, biostatistics, bioinformatics, and computational biology. Integration of these fields enables better understanding of etiologic heterogeneity, disease continuum, causal inference, and the impact of environment, diet, lifestyle, host factors (including genetics and immunity), and their interactions on disease evolution. Hence, the Second International MPE Meeting was held in Boston in December 2014, with aims to: (1) develop conceptual and practical frameworks; (2) cultivate and expand opportunities; (3) address challenges; and (4) initiate the effort of specifying guidelines for MPE. The meeting mainly consisted of presentations of method developments and recent data in various malignant neoplasms and tumors (breast, prostate, ovarian and colorectal cancers, renal cell carcinoma, lymphoma, and leukemia), followed by open discussion sessions on challenges and future plans. In particular, we recognized need for efforts to further develop statistical methodologies. This meeting provided an unprecedented opportunity for interdisciplinary collaboration, consistent with the purposes of the Big Data to Knowledge, Genetic Associations and Mechanisms in Oncology, and Precision Medicine Initiative of the US National Institute of Health. The MPE meeting series can help advance transdisciplinary population science and optimize training and education systems for twenty-first century medicine and public health.
KW - Epidemiologic method
KW - Molecular pathologic epidemiology
KW - Personalized medicine
KW - Systems biology
KW - Translational epidemiology
KW - Unique disease principle
UR - http://www.scopus.com/inward/record.url?scp=84930931584&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930931584&partnerID=8YFLogxK
U2 - 10.1007/s10552-015-0596-2
DO - 10.1007/s10552-015-0596-2
M3 - Review article
C2 - 25956270
AN - SCOPUS:84930931584
SN - 0957-5243
VL - 26
SP - 959
EP - 972
JO - Cancer Causes and Control
JF - Cancer Causes and Control
IS - 7
ER -
